RecruitingPhase 4NCT05935358
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Octapharma
- Principal Investigator
- Shveta Gupta, MDArnold Palmer Hospital for Children
- Intervention
- Nuwiq(drug)
- Enrollment
- 28 enrolled
- Eligibility
- 12 years · MALE
- Timeline
- 2023 – 2026
Study locations (18)
- UT Southwestern Medical Center, Dallas, Texas, United States
- University Hospital Centre Zagreb, Zagreb, Croatia
- Helsinki University Hospital, Helsinki, Finland
- CHU de Nantes Hôtel-Dieu, Nantes, France
- CHRU de Tours, Tours, France
- Vivantes Klinikum im Friedrichshein (KFH), Berlin, Germany
- Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany
- Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg, Germany
- Christian Medical College Vellore, Vellore, Tamil Nadu, India
- St. John's Medical College Hospital, Bengaluru, India
- Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy
- Azienda Ospedaliero Universitaria Careggi - Centro Emofilia, Florence, Italy
- Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital, Milan, Italy
- Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia, Skopje, North Macedonia
- Clinical Center for Serbia Belgrade, Belgrade, Serbia
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05935358 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.